VRNA
Verona PharmaVRNA
VRNA
About: Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which will treat chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and other respiratory diseases, including asthma.
Employees: 209
0
Funds holding %
of 7,407 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
342% more first-time investments, than exits
New positions opened: 53 | Existing positions closed: 12
325% more call options, than puts
Call options by funds: $71.2M | Put options by funds: $16.7M
109% more funds holding in top 10
Funds holding in top 10: 11 [Q3] → 23 (+12) [Q4]
63% more capital invested
Capital invested by funds: $1.95B [Q3] → $3.19B (+$1.24B) [Q4]
27% more funds holding
Funds holding: 150 [Q3] → 191 (+41) [Q4]
0.07% more ownership
Funds ownership: 10.41% [Q3] → 10.48% (+0.07%) [Q4]
5% less repeat investments, than reductions
Existing positions increased: 57 | Existing positions reduced: 60
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$72
22%
upside
Avg. target
$80
36%
upside
High target
$93
58%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
Wells Fargo Tiago Fauth 33% 1-year accuracy 9 / 27 met price target | 58%upside $93 | Overweight Maintained | 28 Feb 2025 |
HC Wainwright & Co. Raghuram Selvaraju 30% 1-year accuracy 99 / 335 met price target | 27%upside $75 | Buy Maintained | 28 Feb 2025 |
Canaccord Genuity Edward Nash 58% 1-year accuracy 11 / 19 met price target | 22%upside $72 | Buy Maintained | 12 Feb 2025 |
Financial journalist opinion
Positive
Seeking Alpha
1 week ago
Verona Pharma's Bull Case Holds, But Lifecycle Extension Is Critical
Ohtuvayre's robust launch for COPD treatment exceeded expectations, with Q4 revenue of $36.6 million and FY24 revenue of $42.3 million, indicating strong market demand. Verona's financial health is solid with $399.757 million in cash, providing a cash runway into 2028, despite a net loss of $33.8 million in Q4. Verona is extending Ohtuvayre's life cycle through new formulations and fixed-dose combinations, aiming for cash flow break-even with a quarterly run rate near $300 million.
Neutral
GlobeNewsWire
3 weeks ago
Verona Pharma Announces Amended Strategic Financing with Oaktree and OMERS
RIPSA interests repurchased Term loan facility increased to $450 million with more favorable terms Access to up to an additional $200 million LONDON and RALEIGH, N.C., March 28, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a biopharmaceutical company focused on respiratory diseases, has amended its existing strategic financing agreements by repaying the revenue interest purchase and sale agreement (“RIPSA”) and increasing the debt facility to $450 million on improved terms with funds managed by Oaktree Capital Management, L.P.
Neutral
Seeking Alpha
1 month ago
Verona Pharma plc (VRNA) Q4 2024 Earnings Call Transcript
Verona Pharma plc (NASDAQ:VRNA ) Q4 2024 Earnings Conference Call February 27, 2024 9:00 AM ET Company Participants David Zaccardelli - President and CEO Mark Hahn - CFO Christopher Martin - CCO Conference Call Participants Andrew Tsai - Jefferies Yasmeen Rahimi - Piper Sandler Tiago Fauth - Wells Fargo Tom Shrader - BTIG Ram Selvaraju - HCW Joon Lee - Truist Boobalan Pachaiyappan - ROTH Operator Good morning ladies and gentlemen. Welcome to the Verona Pharma Fourth Quarter and Full Year 2024 Financial Results and Conference Call.
Neutral
GlobeNewsWire
1 month ago
Verona Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
Ohtuvayre TM (ensifentrine) recorded net product sales of $36.6 million in Q4 and $42.3 million in 2024
Neutral
GlobeNewsWire
1 month ago
Verona Pharma Announces March 2025 Investor Conference Participation
LONDON and RALEIGH, N.C., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that senior management will present a company overview at the following conferences in March 2025:
Neutral
GlobeNewsWire
2 months ago
Verona Pharma to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update
LONDON and RALEIGH, N.C., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that it will report its financial results for the fourth quarter and full year ended December 31, 2024 on Thursday, February 27, 2025 and host an investment community conference call at 9:00 a.m. EST / 2:00 p.m. GMT to discuss these financial results and provide a corporate update.
Positive
Zacks Investment Research
2 months ago
What Makes Verona Pharma (VRNA) a Good Fit for 'Trend Investing'
If you are looking for stocks that are well positioned to maintain their recent uptrend, Verona Pharma (VRNA) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Positive
Zacks Investment Research
2 months ago
Here's Why 'Trend' Investors Would Love Betting on Verona Pharma (VRNA)
Verona Pharma (VRNA) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Positive
Investors Business Daily
3 months ago
Why Verona Pharma, A Triple-Digit Gainer In 2024, Surged Another 22% This Week
Verona Pharma stock hit a record high Thursday on continued enthusiasm for its newly launched COPD treatment, Ohtuvayre. The post Why Verona Pharma, A Triple-Digit Gainer In 2024, Surged Another 22% This Week appeared first on Investor's Business Daily.
Positive
Zacks Investment Research
3 months ago
Wall Street Analysts See a 30.65% Upside in Verona Pharma (VRNA): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 30.7% in Verona Pharma (VRNA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Charts implemented using Lightweight Charts™